<DOC>
	<DOCNO>NCT00645229</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety ziprasidone acute exacerbation schizophrenia schizoaffective disorder , include patient recent onset symptom</brief_summary>
	<brief_title>A Study Efficacy Safety Ziprasidone Patients With Acute Exacerbation Schizophrenia Schizoaffective Disorder</brief_title>
	<detailed_description>The study prematurely discontinue due difficulty subject recruitment March 24 , 2005 . There safety concern lead decision terminate .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Patients currently treat antipsychotic medication neuroleptic naive patient Diagnosis schizophrenia schizoaffective disorder Antipsychotic treatment prior screen cumulative period le 5 year Patients immediate risk commit harm self others Treatment clozapine within 3 month prior baseline History neuroleptic treatment Current antipsychotic treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>